Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer (TNBC) Interventions: Drug: Camrelizumab; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Docetaxel Sponsor: Aiping Shi Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research | Taxotere